Department of Anesthesiology and Intensive Care, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France.
J Am Coll Cardiol. 2013 Feb 26;61(8):820-9. doi: 10.1016/j.jacc.2012.11.054. Epub 2013 Jan 16.
The aim of this analysis was to assess the association between elevated blood glucose level and mortality in acute heart failure (AHF).
Elevated blood glucose has been reported to be prognostically meaningful in patients with cardiac diagnoses, such as coronary artery disease. The short-term prognostic impact of hyperglycemia in AHF is unknown, however.
In a multinational cohort of AHF, we examined the ability of blood glucose concentrations at presentation to predict all-cause mortality by 30 days. Fully adjusted models for prognosis included a previous diagnosis of diabetes mellitus as a covariate.
A total of 6,212 subjects with AHF (mean age, 72 years; 52.5% male) were studied; the median blood glucose concentration on arrival at the hospital was 7.5 mmol/l (135 mg/dl), and 41% had a previous diagnosis of diabetes mellitus (DM). After 30 days, 618 patients (10%) had died. Compared with survivors, decedents had significantly higher median blood glucose concentrations (8.9 mmol/l vs. 7.4 mmol/l; p < 0.0001). In the fully adjusted model, an elevated blood glucose level was an independent predictor of 30-day mortality in AHF (odds ratio: 2.19; 95% confidence interval: 1.69 to 2.83; p < 0.001). The risk associated with an elevated blood glucose level appeared consistent across all subgroups of patients, including patients with preserved (hazard ratio: 5.41; 95% confidence interval: 2.44 to 12.0; p < 0.0001) and impaired systolic function (hazard ratio: 2.37; 95% confidence interval: 1.57 to 3.59; p < 0.0001). Furthermore, in reclassification analyses, elevated blood glucose added significant prognostic information to clinical parameters alone (4.4% net reclassification improvement; p = 0.01).
Among patients with AHF, blood glucose concentrations at presentation are powerfully prognostic for 30-day mortality, independent of a diagnosis of diabetes mellitus or other clinical variables. Because blood glucose is easily modifiable, it may represent a valid target for therapeutic intervention.
本分析旨在评估急性心力衰竭(AHF)患者血糖升高与死亡率之间的关系。
已有研究表明,血糖升高与冠心病等心脏诊断患者的预后有关。然而,AHF 患者短期高血糖的预后影响尚不清楚。
在一项多中心 AHF 患者队列研究中,我们通过 30 天全因死亡率评估了入院时血糖浓度预测死亡率的能力。预后的完全调整模型将糖尿病前期诊断作为协变量。
共纳入 6212 例 AHF 患者(平均年龄 72 岁,52.5%为男性);入院时的中位血糖浓度为 7.5mmol/L(135mg/dl),41%有糖尿病前期诊断(DM)。30 天后,618 例患者(10%)死亡。与存活者相比,死亡者的中位血糖浓度显著升高(8.9mmol/L 比 7.4mmol/L;p<0.0001)。在完全调整的模型中,血糖升高是 AHF 30 天死亡率的独立预测因素(优势比:2.19;95%置信区间:1.69 至 2.83;p<0.001)。在包括心功能保留(危险比:5.41;95%置信区间:2.44 至 12.0;p<0.0001)和心功能受损(危险比:2.37;95%置信区间:1.57 至 3.59;p<0.0001)的所有患者亚组中,高血糖水平与风险相关,且具有一致性。此外,在再分类分析中,与临床参数相比,高血糖水平显著增加了预后信息(4.4%净再分类改善;p=0.01)。
在 AHF 患者中,入院时的血糖浓度对 30 天死亡率具有强大的预后预测能力,与糖尿病前期诊断或其他临床变量无关。由于血糖易于调节,因此它可能是治疗干预的有效靶点。